Six men hospitalized after clinical trial goes awry
All six people taking the experimental drug TGN1412 from Germany's TeGenero fell ill and two were in critical care in a London hospital, according to British newspapers. TGN1412 is a monoclonal antibody designed to treat leukemia, rheumatoid arthritis and other inflammatory diseases. A spokesman for the Association of the British Pharmaceutical Industry said it was extremely rare to see this kind of reaction in a clinical trial. The trial has been suspended until investigators can figure out what caused such severe adverse events.
- here's the report from The Guardian
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
